Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72


A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC.

Blood. 2011 Aug 4;118(5):1255-63. doi: 10.1182/blood-2011-02-337360. Epub 2011 Jun 7.


Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.


Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.

Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11.


Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene.

Guillot-Delost M, Cheraï M, Hamel Y, Rosenzwajg M, Baillou C, Simonin G, Leclercq V, Mariotti-Ferrandiz ME, Six A, Bon-Durand V, Maury S, Salomon BL, Cohen JL, Klatzmann D, Lemoine FM.

J Gene Med. 2008 Aug;10(8):834-46. doi: 10.1002/jgm.1220.


Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES.

Clin Cancer Res. 2002 Jun;8(6):1720-30.


Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.

Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y, Kimura A.

J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.


Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.

Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A.

Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.


Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.

Correia DV, d'Orey F, Cardoso BA, Lança T, Grosso AR, deBarros A, Martins LR, Barata JT, Silva-Santos B.

PLoS One. 2009 May 21;4(5):e5657. doi: 10.1371/journal.pone.0005657.


IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.

Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H.

Int J Cancer. 2015 Feb 15;136(4):821-30. doi: 10.1002/ijc.29037. Epub 2014 Jun 26.


The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S.

Cell. 1991 Jul 26;66(2):233-43.


Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.

Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, Tatematsu M.

Cancer Sci. 2008 Jul;99(7):1471-8. doi: 10.1111/j.1349-7006.2008.00821.x. Epub 2008 Apr 16.


A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.

Yang S, Archer GE, Flores CE, Mitchell DA, Sampson JH.

Cancer Immunol Immunother. 2013 Nov;62(11):1649-62. doi: 10.1007/s00262-013-1464-0. Epub 2013 Aug 27.


Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.

Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC.

Mol Immunol. 2013 Nov;56(1-2):1-11. doi: 10.1016/j.molimm.2013.03.021. Epub 2013 Apr 27.


The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help.

Fulcher DA, Lyons AB, Korn SL, Cook MC, Koleda C, Parish C, Fazekas de St Groth B, Basten A.

J Exp Med. 1996 May 1;183(5):2313-28.


HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulitis to NOD-scid/γc(null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells.

Whitfield-Larry F, Young EF, Talmage G, Fudge E, Azam A, Patel S, Largay J, Byrd W, Buse J, Calikoglu AS, Shultz LD, Frelinger JA.

Diabetes. 2011 Jun;60(6):1726-33. doi: 10.2337/db10-1287. Epub 2011 Apr 26.


Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.


Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089. Epub 2011 Jun 14.


A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.


Gamma delta T cells differentiate into a functional but nonproliferative state during a normal immune response.

Spaner D, Migita K, Ochi A, Shannon J, Miller RG, Pereira P, Tonegawa S, Phillips RA.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8415-9.

Supplemental Content

Support Center